$REGN (REGENERON PHARMACEUTICALS) — 8-K: Regeneron Expands Sanofi Antibody Pact With $1.0 Billion Upfront Payment

Regeneron and Sanofi amended their Antibody License and Collaboration Agreement to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4R alpha, and IL-4xIL-13. Sanofi will make a $1.0 billion upfront payment to Regeneron, with up to an additional $7.0 billion in aggregate development, regulatory, and commercial milestone payments. Global profits on the new products will be shared equally, and development costs will be shared equally subject to a budget cap, with excess costs borne by Regeneron. Regeneron will lead development and pre-approval regulatory work, and remain lead regulatory party and commercializer in the United States, while Sanofi leads commercialization and ex-U.S. regulatory.

Regeneron and Sanofi amended their Antibody License and Collaboration Agreement to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4R alph